Trovagene is a clinical-stage, oncology therapeutics company, taking a precision medicine approach and integrating a biomarker strategy to develop targeted drugs to treat leukemias, lymphomas and solid tumor cancers. Our drug candidate, onvansertib, is a first-in-class, 3rd generation Polo-like Kinase Inhibitor with best-in-class attributes. Onvansertib is highly-selective for PLK1, which is over-expressed in most cancers; it is orally administered; synergistic in combination with numerous chemotherapies and targeted therapeutics; has a half-life of 24-hours which allows for flexibility in dosing and schedule. We are developing onvansertib as part of combination regimens with already approved drugs for the treatment of cancers and indications where there is a significant medical need for new treatment options. Source
No articles found.
Gali Health, Inc. is a San Francisco-based consumer-focused health technology comp...
Gali Health, Inc. is a San Francisco-based cons...
Bellicum Pharmaceuticals is a clinical-stage biopharmaceutical company focused on ...
Bellicum Pharmaceuticals is a clinical-stage bi...
The Healthereum Patient Behavior Management platform is a full cycle communication...
The Healthereum Patient Behavior Management pla...
Sorrentoâs lead programs with short-term milestones consist of two clinical stag...
Sorrentoâs lead programs with short-term mile...
Adamas Pharmaceuticals, Inc. is using its deep understanding of time-dependent bio...
Adamas Pharmaceuticals, Inc. is using its deep ...
Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on ...
Alder BioPharmaceuticals is a clinical-stage bi...
ViewRayÂŽ Inc., (NASDAQ:VRAY), designs, manufactures and markets MRIdianÂŽ the wor...
ViewRayÂŽ Inc., (NASDAQ:VRAY), designs, manufac...
Join the National Investor Network and get the latest information with your interests in mind.